Detalhe da pesquisa
1.
Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
BMC Nephrol
; 21(1): 262, 2020 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32646385
2.
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
BMC Nephrol
; 20(1): 359, 2019 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31521117
3.
Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy.
G Ital Dermatol Venereol
; 155(4): 441-451, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29582617
4.
Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.
Expert Opin Biol Ther
; 18(3): 309-315, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186988
5.
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Drug Saf
; 41(11): 1013-1022, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29796832
6.
Pharmacokinetics of new oral anticoagulants: implications for use in routine care.
Expert Opin Drug Metab Toxicol
; 14(10): 1057-1069, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30277082
7.
Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy.
Drug Saf
; 41(1): 111-123, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28766109
8.
Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.
Front Pharmacol
; 9: 608, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29937731
9.
Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.
Clin Drug Investig
; 38(3): 269-278, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29076054
10.
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy.
Clin Drug Investig
; 38(3): 279-285, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29289999
11.
Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014.
Front Endocrinol (Lausanne)
; 9: 95, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29593655
12.
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
PLoS One
; 11(5): e0155805, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27187174
13.
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
BioDrugs
; 30(4): 295-306, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27138636